Synairgen PLC (AIM:SNG, OTC:SYGGF) has appointed Gareth Walters, who brings 30 years’ expertise in global regulatory strategy, to the newly-created role of chief regulatory officer in preparation for regulatory submissions for its SNG001 product.
Chief executive Richard Marsden said: “His experience and expertise in global regulatory strategy will be invaluable as we prepare for SNG001 regulatory submissions.”
Dr Walters previously served as global regulatory affairs head and head of European regulatory affairs for Chugai Pharmaceuticals, where he led strategic and operational regulatory activities in Europe, Japan and the US.
Before this, he held commercial and clinical positions at Roche and various senior regulatory and executive management and board roles at several pharmaceutical and biotech companies, where Synairgen said he played a key role in bringing innovative new medicines to the market, including in the US and Europe.
Walters said: “The anticipated conclusion of the Phase III trial in the coming months for SNG001 is a critical milestone for the company in its goal of bringing interferon beta to hospitalised patients with COVID-19. I look forward to collaborating closely with the team and driving a global regulatory programme that helps deliver a therapy to patients that has the potential to reduce the burden on hospitals and healthcare systems.”
